{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T15:03:18Z","timestamp":1763046198642,"version":"3.45.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"October University for Modern Sciences and Arts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>MicroRNA-183 (miR-183-5p), a noncoding RNA, is upregulated in bladder carcinoma (BC). Although it has been implicated in oncogenesis, its precise regulatory effects and biological functions remain unclear. Tropomyosin-1 (TPM1) was shown to be downregulated in solid tumors and was previously identified as a novel tumor suppressor gene.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Our study focuses on the prognostic, diagnostic, and therapeutic potential of miR-183-5p in bladder carcinoma and assess TPM1 gene targets and their modulatory functions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Urine cytology, cystectomy and transurethral resection (TUR) biopsies from 148 BC patients were collected. TPM1 protein and miR-183-5p expressions were assessed through immunohistochemistry (IHC) and real-time PCR respectively. In vitro assay investigated the effect of miR-183-5p on TPM1mRNA in bladder carcinoma cell lines, then confirmed by comparing miR-183-5p mimics in non-cancerous and urothelial carcinoma cell lines. Concomitant TPM1 gene expression was examined, and the theranostic miR-183-5p potential was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Upregulation of miR-183-5p expression in BC tissue biopsies and urine cytologies was noted, contrasting the downregulation of TPM1 protein expression in the high-grade, high-stage, lymph node metastatic BC tissues (in comparison to non-cancerous, low-grade, low-stage non-lymph node metastasizing BCs). Moreover, the miR-183-5p oncogenic influence was responsive in targeting TPM1 gene at 3\u2032UTR region, and miR\u2011183\u20115p.1 restricted TPM1 expression in T24 cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides the first illustration of the miR-183-5p\u2013TPM1 axis in bladder carcinoma, supporting the theranostic role of miR-183-5p as an onco-miR in BC progression, diagnosis, and prognostication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12672-025-03829-w","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T14:58:13Z","timestamp":1763045893000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of microRNA-183 based theranostics through targeting TPM1 in bladder cancer"],"prefix":"10.1007","volume":"16","author":[{"given":"Samah","family":"Mamdouh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Aboushousha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman","family":"Hemida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rady E.","family":"El-Araby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Elesaily","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3333-5005","authenticated-orcid":false,"given":"Gehan","family":"Hammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Magdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"3829_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3829_CR2","doi-asserted-by":"publisher","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran A, Cookson MS, Guercio BJ, et al. Advances in diagnosis and treatment of bladder cancer. BMJ. 2024;384:e076743.","journal-title":"BMJ"},{"key":"3829_CR3","unstructured":"International Agency for Research on Cancer. Urinary and Male Genital Tumours. International Agency for Research on Cancer. https:\/\/tumourclassification.iarc.who.int (2022, accessed 8 May 2024)."},{"key":"3829_CR4","doi-asserted-by":"publisher","unstructured":"Shalata AT, Shehata M, Van Bogaert E et al. Predicting recurrence of Non-Muscle-Invasive bladder cancer: current techniques and future Trends. Cancers (Basel); 14. Epub ahead of print 1 October 2022. https:\/\/doi.org\/10.3390\/CANCERS14205019","DOI":"10.3390\/CANCERS14205019"},{"key":"3829_CR5","doi-asserted-by":"publisher","first-page":"6546","DOI":"10.21037\/tcr.2020.01.36","volume":"9","author":"HH Lee","year":"2020","unstructured":"Lee HH, Ham WS. Perioperative immunotherapy in muscle-invasive bladder cancer. Transl Cancer Res. 2020;9:6546\u201353.","journal-title":"Transl Cancer Res"},{"key":"3829_CR6","doi-asserted-by":"publisher","first-page":"27656","DOI":"10.18632\/oncotarget.24441","volume":"9","author":"JY Lee","year":"2018","unstructured":"Lee JY, Yun SJ, Jeong P, et al. Identification of differentially expressed MiRNAs and miRNA-targeted genes in bladder cancer. Oncotarget. 2018;9:27656.","journal-title":"Oncotarget"},{"key":"3829_CR7","doi-asserted-by":"publisher","unstructured":"Hu X, Li G, Wu S. Advances in diagnosis and therapy for bladder Cancer. Cancers (Basel); 14. Epub ahead of print 1 July 2022. https:\/\/doi.org\/10.3390\/CANCERS14133181","DOI":"10.3390\/CANCERS14133181"},{"key":"3829_CR8","doi-asserted-by":"publisher","unstructured":"Addanki S, Meas S, Sarli VN et al. Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers. Int J Mol Sci; 23. Epub ahead of print 1 July 2022. https:\/\/doi.org\/10.3390\/IJMS23147843","DOI":"10.3390\/IJMS23147843"},{"key":"3829_CR9","first-page":"68","volume":"30","author":"S Mamdouh","year":"2023","unstructured":"Mamdouh S, Hammad G, Aboushousha T, et al. Diagnostic performances of urine cytology and TERT promoter mutations in bladder cancer. J Popul Ther Clin Pharmacol. 2023;30:68\u201383.","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"3829_CR10","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1080\/21655979.2021.1956404","volume":"12","author":"K Long","year":"2021","unstructured":"Long K, Dong Q, Zeng W. The clinical significance of microRNA-409 in pancreatic carcinoma and associated tumor cellular functions. Bioengineered. 2021;12:4633.","journal-title":"Bioengineered"},{"key":"3829_CR11","doi-asserted-by":"publisher","unstructured":"Kumar M, Li G. Emerging Role of MicroRNA-30c in Neurological Disorders. Int J Mol Sci; 24. Epub ahead of print 1 January 2022. https:\/\/doi.org\/10.3390\/IJMS24010037","DOI":"10.3390\/IJMS24010037"},{"key":"3829_CR12","doi-asserted-by":"publisher","unstructured":"Zhang M, Lu Y, Wang L et al. Current status of research on small extracellular vesicles for the diagnosis and treatment of urological Tumors. Cancers (Basel); 15. Epub ahead of print 1 January 2023. https:\/\/doi.org\/10.3390\/CANCERS15010100","DOI":"10.3390\/CANCERS15010100"},{"key":"3829_CR13","doi-asserted-by":"publisher","first-page":"24184","DOI":"10.1073\/pnas.1913307116","volume":"116","author":"IP Michael","year":"2019","unstructured":"Michael IP, Saghafinia S, Hanahan D. A set of MicroRNAs coordinately controls tumorigenesis, invasion, and metastasis. Proc Natl Acad Sci U S A. 2019;116:24184\u201395.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3829_CR14","doi-asserted-by":"publisher","unstructured":"Davies M, Davey MG, Miller N. The potential of MicroRNAs as clinical biomarkers to aid ovarian cancer diagnosis and Treatment. Genes (Basel); 13. Epub ahead of print 1 November 2022. https:\/\/doi.org\/10.3390\/GENES13112054","DOI":"10.3390\/GENES13112054"},{"key":"3829_CR15","doi-asserted-by":"publisher","unstructured":"Urabe F, Matsuzaki J, Ito K et al. Serum MicroRNA as liquid biopsy biomarker for the prediction of oncological outcomes in patients with bladder cancer. Int J Urol; 29. Epub ahead of print 2022. https:\/\/doi.org\/10.1111\/IJU.14858","DOI":"10.1111\/IJU.14858"},{"key":"3829_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3109\/10408363.2014.906130","volume":"51","author":"D Dietrich","year":"2014","unstructured":"Dietrich D, Meller S, Uhl B, et al. Nucleic acid-based tissue biomarkers of urologic malignancies. Crit Rev Clin Lab Sci. 2014;51:173\u201399.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"3829_CR17","first-page":"5056","volume":"15","author":"JM Gao","year":"2018","unstructured":"Gao JM, Huang LZ, Huang ZG, et al. Clinical value and potential pathways of miR-183-5p in bladder cancer: A study based on miRNA-seq data and bioinformatics analysis. Oncol Lett. 2018;15:5056\u201370.","journal-title":"Oncol Lett"},{"key":"3829_CR18","doi-asserted-by":"publisher","first-page":"7173","DOI":"10.1093\/nar\/gkv703","volume":"43","author":"S Dambal","year":"2015","unstructured":"Dambal S, Shah M, Mihelich B, et al. The microRNA-183 cluster: the family that plays together stays together. Nucleic Acids Res. 2015;43:7173\u201388.","journal-title":"Nucleic Acids Res"},{"key":"3829_CR19","first-page":"2519","volume":"7","author":"W Gu","year":"2014","unstructured":"Gu W, Gao T, Shen J, et al. MicroRNA-183 inhibits apoptosis and promotes proliferation and invasion of gastric cancer cells by targeting PDCD4. Int J Clin Exp Med. 2014;7:2519.","journal-title":"Int J Clin Exp Med"},{"key":"3829_CR20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2174\/1871520615666150914114237","volume":"16","author":"C Li","year":"2016","unstructured":"Li C, Deng L, Zhi Q, et al. MicroRNA-183 functions as an oncogene by regulating PDCD4 in gastric cancer. Anticancer Agents Med Chem. 2016;16:447\u201355.","journal-title":"Anticancer Agents Med Chem"},{"key":"3829_CR21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3892\/ol.2015.3872","volume":"11","author":"F Miao","year":"2016","unstructured":"Miao F, Zhu J, Chen Y, et al. MicroRNA-183-5p promotes the proliferation, invasion and metastasis of human pancreatic adenocarcinoma cells. Oncol Lett. 2016;11:134\u201340.","journal-title":"Oncol Lett"},{"key":"3829_CR22","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1038\/bjc.2014.228","volume":"110","author":"K Tanaka","year":"2014","unstructured":"Tanaka K, Shimura T, Kitajima T, et al. Tropomyosin-related receptor kinase B at the invasive front and tumour cell dedifferentiation in gastric cancer. Br J Cancer. 2014;110:2923\u201334.","journal-title":"Br J Cancer"},{"key":"3829_CR23","first-page":"2371","volume":"42","author":"J Lin","year":"2019","unstructured":"Lin J, Shen J, Yue H, et al. miRNA-183-5p.1 promotes the migration and invasion of gastric cancer AGS cells by targeting TPM1. Oncol Rep. 2019;42:2371.","journal-title":"Oncol Rep"},{"key":"3829_CR24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/978-0-387-85766-4_10","volume":"644","author":"DM Helfman","year":"2008","unstructured":"Helfman DM, Flynn P, Khan P, et al. Tropomyosin as a regulator of cancer cell transformation. Adv Exp Med Biol. 2008;644:124\u201331.","journal-title":"Adv Exp Med Biol"},{"key":"3829_CR25","doi-asserted-by":"crossref","unstructured":"Wojcik EM, Kurtycz DFI, Rosenthal DL. The Paris System for Reporting Urinary Cytology: Second Edition. The Paris System for Reporting Urinary Cytology: Second Edition. 2022; 1\u2013329.","DOI":"10.1007\/978-3-030-88686-8"},{"key":"3829_CR26","doi-asserted-by":"publisher","unstructured":"Yilmaz A, Onen HI, Alp E et al. Real-Time PCR for gene expression Analysis. Polymerase chain Reaction. Epub ahead of print 30 May 2012. https:\/\/doi.org\/10.5772\/37356","DOI":"10.5772\/37356"},{"key":"3829_CR27","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1111\/j.1365-2036.2006.02856.x","volume":"23","author":"M Venerito","year":"2006","unstructured":"Venerito M, Treiber G, Wex T, et al. Effects of low-dose aspirin on gastric erosions, cyclooxygenase expression and mucosal prostaglandin-E2 do not depend on Helicobacter pylori infection. Aliment Pharmacol Ther. 2006;23:1225\u201333.","journal-title":"Aliment Pharmacol Ther"},{"key":"3829_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cell.2004.12.035","volume":"120","author":"BP Lewis","year":"2005","unstructured":"Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are MicroRNA targets. Cell. 2005;120:15\u201320.","journal-title":"Cell"},{"key":"3829_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1101\/gr.082701.108","volume":"19","author":"RC Friedman","year":"2009","unstructured":"Friedman RC, Farh KKH, Burge CB, et al. Most mammalian mRNAs are conserved targets of MicroRNAs. Genome Res. 2009;19:92\u2013105.","journal-title":"Genome Res"},{"key":"3829_CR30","doi-asserted-by":"publisher","unstructured":"Agarwal V, Bell GW, Nam JW et al. Predicting effective MicroRNA target sites in mammalian mRNAs. Elife; 4. Epub ahead of print 12 August 2015. https:\/\/doi.org\/10.7554\/ELIFE.05005","DOI":"10.7554\/ELIFE.05005"},{"key":"3829_CR31","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.molcel.2010.06.005","volume":"38","author":"C Shin","year":"2010","unstructured":"Shin C, Nam JW, Farh KKH, et al. Expanding the MicroRNA targeting code: functional sites with centered pairing. Mol Cell. 2010;38:789.","journal-title":"Mol Cell"},{"key":"3829_CR32","unstructured":"UCSC Genome Browser Home. https:\/\/genome.ucsc.edu\/ (accessed 9 May 2024)."},{"key":"3829_CR33","doi-asserted-by":"crossref","unstructured":"Zhang Y et al. Cao | Huake, Yang | Feixiang, Comprehensive analyses of nuclear mitochondria-related genes in the molecular features, immune infiltration, and drug sensitivity of clear cell renal cell carcinoma. Medicine Advances. 2024; 2: 238\u2013253.","DOI":"10.1002\/med4.72"},{"key":"3829_CR34","doi-asserted-by":"crossref","unstructured":"Ibrahim AH, Shash E. General oncology care in Egypt. Cancer Arab World 2022; 41\u201361.","DOI":"10.1007\/978-981-16-7945-2_4"},{"key":"3829_CR35","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.2217\/fon-2022-0448","volume":"18","author":"X Li","year":"2022","unstructured":"Li X, Chen W, Li R, et al. Bladder cancer diagnosis with a four-miRNA panel in serum. Future Oncol. 2022;18:3311\u201322.","journal-title":"Future Oncol"},{"key":"3829_CR36","doi-asserted-by":"publisher","unstructured":"Grimaldi AM, Lapucci C, Salvatore M et al. Urinary miRNAs as a Diagnostic Tool for Bladder Cancer: A Systematic Review. Biomedicines; 10. Epub ahead of print 1 November 2022. https:\/\/doi.org\/10.3390\/BIOMEDICINES10112766","DOI":"10.3390\/BIOMEDICINES10112766"},{"key":"3829_CR37","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1007\/s11033-021-06451-5","volume":"48","author":"AS El-Shal","year":"2021","unstructured":"El-Shal AS, Shalaby SM, Abouhashem SE, et al. Urinary Exosomal microRNA-96-5p and microRNA-183-5p expression as potential biomarkers of bladder cancer. Mol Biol Rep. 2021;48:4361\u201371.","journal-title":"Mol Biol Rep"},{"key":"3829_CR38","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000371507","volume":"59","author":"S Wei","year":"2015","unstructured":"Wei S, Bing Z, Yao Y, et al. Higher expression of miR-182 in cytology specimens of High-Grade urothelial cell carcinoma: A potential diagnostic marker. Acta Cytol. 2015;59:109\u201312.","journal-title":"Acta Cytol"},{"key":"3829_CR39","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/j.1349-7006.2010.01816.x","volume":"102","author":"Y Yamada","year":"2011","unstructured":"Yamada Y, Enokida H, Kojima S, et al. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci. 2011;102:522\u20139.","journal-title":"Cancer Sci"},{"key":"3829_CR40","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s12094-014-1183-9","volume":"16","author":"F Xu","year":"2014","unstructured":"Xu F, Zhang H, Su Y, et al. Up-regulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers. Clin Transl Oncol. 2014;16:980\u20135.","journal-title":"Clin Transl Oncol"},{"key":"3829_CR41","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1080\/15384047.2018.1480279","volume":"19","author":"G Liu","year":"2018","unstructured":"Liu G, Zhao X, Zhou J, et al. Long non-coding RNA MEG3 suppresses the development of bladder urothelial carcinoma by regulating miR-96 and TPM1. Cancer Biol Ther. 2018;19:1039.","journal-title":"Cancer Biol Ther"},{"key":"3829_CR42","doi-asserted-by":"publisher","unstructured":"Humayun-Zakaria N, Arnold R, Goel A et al. Tropomyosins: Potential Biomarkers for Urothelial Bladder Cancer. Int J Mol Sci; 20. Epub ahead of print 1 March 2019. https:\/\/doi.org\/10.3390\/IJMS20051102","DOI":"10.3390\/IJMS20051102"},{"key":"3829_CR43","doi-asserted-by":"publisher","unstructured":"Yan Y, Li J, Ye M et al. Tropomyosin Is Potential Markers for the Diagnosis and Prognosis of Bladder Cancer. Dis Markers; 2022. Epub ahead of print 2022. https:\/\/doi.org\/10.1155\/2022\/6936262","DOI":"10.1155\/2022\/6936262"},{"key":"3829_CR44","doi-asserted-by":"publisher","unstructured":"Li H, Chen J, Li Z et al. S100A5 attenuates efficiency of Anti-PD-L1\/PD-1 immunotherapy by inhibiting CD8\u2009+\u2009T Cell-Mediated Anti-Cancer immunity in bladder Carcinoma. Adv sci (Weinh); 10. Epub ahead of print 5 September 2023. https:\/\/doi.org\/10.1002\/ADVS.202300110","DOI":"10.1002\/ADVS.202300110"},{"key":"3829_CR45","first-page":"4828","volume":"22","author":"D Chen","year":"2018","unstructured":"Chen D, Li SG, Chen JY, et al. MiR-183 maintains canonical Wnt signaling activity and regulates growth and apoptosis in bladder cancer via targeting AXIN2. Eur Rev Med Pharmacol Sci. 2018;22:4828\u201336.","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03829-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03829-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03829-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T14:58:16Z","timestamp":1763045896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03829-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3829"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03829-w","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the TBRI ethics committee, under the Federal Wide Assurance No. FWA00010609, in Cairo, Egypt, according to the 18th WMA General Assembly, Helsinki, Finland, June 1964, regulations. Informed consent was acquired from all participants in writing prior to sample collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2100"}}